12:00 AM
 | 
Jan 11, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zerenex ferric citrate regulatory update

Keryx received an SPA from FDA for a planned Phase III program to evaluate Zerenex ferric citrate to treat hyperphosphatemia in patients with end-stage renal disease (ESRD). The program will include a pair of Phase III trials. The first, which is expected to...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >